Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 147 for your search:
Cancer Type/Condition:
Brain tumor, adult: Glioblastoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase III Randomized Study of Concurrent Chemoradiotherapy and Adjuvant Temozolomide With Versus Without Bevacizumab in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
RTOG-0825
, RTOG 0825, NCT00884741
2.
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
EF-14
, NCT00916409
3.
A Phase I/II Study of the Photon Radiosurgery System
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 to 32
Sponsor:
Other
Protocol IDs:
CNS 0201
, NCT00179907
4.
Phase I/II Study of GP96 Heat Shock Protein-Peptide Complex Vaccine in Patients With Recurrent or Progressive High-Grade Glioma (Phase I Study Closed to Accrual as of 7/25/2007)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCSF-05103
, 05103, UCSF-H41995-27311-01, NCT00293423
5.
Phase I/II Study of ZD6474 in Patients With Recurrent High-Grade or Progressive Low-Grade Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-06-C-0063
, NCI-P6680, NCT00293566
6.
Phase I/II Study of Sorafenib and Temsirolimus in Patients With Recurrent Glioblastoma (Phase I Closed to Accrual as of 11/21/07)
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N0572
, N0572, NCT00329719
7.
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
501007705
, NCT00301418
8.
Phase I/II Study of Sorafenib in Combination With Erlotinib Hydrochloride, Tipifarnib, or Temsirolimus in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-05-02
, NABTC-05-02, NCT00335764
9.
Phase I/II Study of Tandutinib in Patients With Recurrent or Progressive Glioblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-0504
, NABTT-0504, NABTT-0504, NCT00379080
10.
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
021-003
, NCT00394628
11.
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06-377
, IRUSZACT0018, NCT00441142
12.
Intracerebral Clysis in Treating Patients With Recurrent Primary Brain Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 120
Sponsor:
Other
Protocol IDs:
R01 CA 89395-01
, Topotecan, Brain Tumors, Intracerebral Clysis, NCT00452959
13.
Radiosurgery for Glioblastoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 65
Sponsor:
Other
Protocol IDs:
2006P-000464
, NCT00456612
14.
Phase I/II Study of Hydroxychloroquine, Radiotherapy, and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
ABTC-0603
, NABTT-0603, 0603, NCT00486603
15.
Phase I/II Study of Erlotinib Hydrochloride and Sirolimus in Patients With Recurrent Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UCLA-0604104
, OSI3781s, NCT00509431
16.
Phase I/II Study of VNP40101M and Temozolomide in Patients With Progressive or Relapsed Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Over 18
Sponsor:
NCI
Protocol IDs:
NU07C1
, NU 07C1, NCT00516282
17.
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
REO 007
, NCT00528684
18.
Phase I/II Study of Everolimus, Temozolomide, and 3D-Conformal Radiotherapy or Intensity-Modulated Radiotherapy Followed by Adjuvant Temozolomide With or Without Everolimus in Patients With Newly Diagnosed Glioblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N057K
, N057K, NCT00553150
19.
Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM)
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2006-0709
, NCT00555399
20.
Phase I/II Randomized Study of Cytomegalovirus-Specific T-Cell Adoptive Transfer in Patients With Newly Diagnosed Glioblastoma Multiforme Who Are Recovering From Therapeutic Temozolomide-Induced Lymphopenia
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
DUMC-PRO00000580
, PRO00000580, DUMC-SPORE Project 3, NCT00627224
21.
Phase I/II Study of BSI-201 and Temozolomide With or Without Radiotherapy in Patients With Newly Diagnosed Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
ABTC-0703
, NABTT-0703, NABTT-0703, NCT00589576
22.
Phase I/II Study of Dose-Intensive Chemotherapy Comprising Temozolomide, Carmustine, and O6-Benzylguanine in Combination with Radiotherapy and Transduced Autologous Stem Cells in Patients with Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
FHCRC-2000.00
, FHCRC-2000.00, 8357, FHCRC-IR-6259, NCT00669669
23.
Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
MPC-6827-07-004
, MPC-6827 GBM, NCT00635557
24.
Phase I/II Study of Cediranib, Temozolomide, and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MGH-07-344
, 07-344, 8030, NCT00662506
25.
Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2008-0059
, NCT00734526
Select All on Page
1
Help with Results
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
RSS
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
